Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Successful trial for anaemia drug

  • Comment

A drug designed to increase red blood cell production in patients with a form of anaemia known as pure-red cell aplasia (PRCA) has been trialled at King’s College Hospital in London.

The New England Journal of Medicine reports that the Affymax drug Hematide resulted in increased cell production in all but one of 14 patients involved in the trial.

PRCA causes a sudden and severe decrease in the number of red blood cells produced by the bone marrow and is associated with chronic kidney disease.

Costly and time-consuming blood transfusions are usually required to treat the condition, which carry risks of infection and organ rejection among kidney patients.That means that additional drugs are often used to suppress the immune system, which in turn can lead to patients developing an even greater risk of infection.

The trial of Hematide, an experimental erythropoiesis-stimulating agent, involved monthly injections over a two-year period.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.